Theravance Biopharma Ireland Limited, an affiliate of Theravance Biopharma, Inc. (Nasdaq: TBPH), entered into a global license agreement with Pfizer Inc. (NYSE: PFE) in December 2019 for its preclinical skin-selective, locally acting pan-JAK inhibitor program. 

However, on June 9, 2023, the company received notice from Pfizer regarding the termination of the license agreement. The termination is set to be effective as of October 7, 2023, as stated in a regulatory filing with the SEC. 

In after-hours, $TBPH was trading at $11.35, showing an increase of $0.33 (+2.99%)

Vail Resorts, Inc. (NYSE: MTN), a leading global hospitality company operating premier mountain resorts, has been maintained with a Hold rating by Truist Securities, while the investment firm raised the price target from $262 to $263. 

With $MTN closing at $239.66 on Friday, this adjusted price target implies a potential upside of $23.34 or 9.73%, as per the analyst's view. 

Additionally, Leonardo DRS, Inc. (Nasdaq: DRS), a prominent technology and defense company, has been initiated with a Buy rating by Truist Securities, which set a price target of $19. 

Based on the closing price of $16.24 on Friday, this price target suggests a potential upside of $2.76 or 17.00% for $DRS, according to the investment banking firm's analysis.

Please note that the potential upside figures are based on Truist Securities' views and may not reflect the actual market performance. Investors should conduct their own research and consider other factors before making any investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)